肝硬化患者纤溶活性变化与临床指征关系的探讨

目的:探讨肝硬化患者纤溶活性增高与组织纤溶酶原激活物(t-PA),组织纤溶酶原激活物抑制剂(PAI)的关系。方法:根据Ch ild-Pugh分级把明确诊断为肝硬化的86例患者分为三级,A级26例,B级30例,C级30例。对每例样本检测组织纤溶酶原激活物(t-PA)抗原,组织纤溶液酶原激活物抑制剂(PAI),纤维蛋白(原)降解产物(FDP)和D-二聚体(D-d im er)。结果:46例具有正常纤溶活性(FDP<5 mg/l;D-d im er<0.5 mg/l)的病例,其中A级26例,B级12例,C级8例,t-PA抗原随病情严重程度而显著性升高(P<0.05),而PAI活性在三组结果近似(P>0.05)。t-PA在纤溶活性高的患者略高于正常纤溶患者,但差异没有显著性意义(P>0.05);PAI在两组间结果近似,差异没有显著性意义(P>0.05)。结论:t-PA随病情加重而显著性升高,PAI随病情加重变化不大。

To investigate the relationship between fibrinolysis and clinical parameters in patients with different degrees of hepatocirrhosis

Objective:To Investigate the relationship between hyperfibrionlysis and tissue plasminogen activator antigen(t-PA),plasminogen activator inhibitor activity(PAI) in patients with different degrees of hepatocirrhosis associated with viral hepatitis.Methods:Eighty-six patients with cirrhosis were divided into three subgroups(A,B,and C) on the basis of Child-Pugh classification.Tissue plasminogen activator antigen(t-PA),plasminogen activator inhibitor activity(PAI),fibrin/fibrinogen degradation products(FDP),and fragment D-dimer were measured in each patients.Results:t-PA antigen was incresed with the grade of cirrhosis in hyperfibrinolysis patient(P<0.05).t-PA and PAI activity had no significant changes in patients between hyperfibrionlysis and normal fibrionlysis.Conclusion:t-PA is a important biomarker in cirrhosis patient with hyperfibronlysis to estimate the grade of cirrhosis.